Moberg Pharma AB (publ) (MOB.ST)
SEK 11.28
(10.37%)
SEK 11.28
(10.37%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 4.73 Million SEK | -22.41% |
| 2022 | 6.1 Million SEK | 55.3% |
| 2021 | 3.93 Million SEK | -46.84% |
| 2020 | 7.39 Million SEK | 0.0% |
| 2018 | 594.51 Million SEK | 0.46% |
| 2017 | 591.78 Million SEK | 0.47% |
| 2016 | 589.04 Million SEK | 17572.97% |
| 2015 | 3.33 Million SEK | -80.0% |
| 2014 | 16.66 Million SEK | -44.45% |
| 2013 | 30 Million SEK | -25.0% |
| 2012 | 40 Million SEK | 0.0% |
| 2011 | - SEK | -100.0% |
| 2010 | 150 Thousand SEK | -50.41% |
| 2009 | 302.5 Thousand SEK | -55.35% |
| 2008 | 677.5 Thousand SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 4.42 Million SEK | -6.59% |
| 2024 Q2 | 3.99 Million SEK | -9.81% |
| 2023 Q2 | 4.43 Million SEK | -8.9% |
| 2023 Q3 | 3.79 Million SEK | -14.27% |
| 2023 Q4 | 4.73 Million SEK | 24.72% |
| 2023 FY | 4.73 Million SEK | -22.41% |
| 2023 Q1 | 4.86 Million SEK | -20.34% |
| 2022 Q3 | 1.77 Million SEK | -48.04% |
| 2022 FY | 6.1 Million SEK | 55.3% |
| 2022 Q4 | 6.1 Million SEK | 244.33% |
| 2022 Q1 | 3.25 Million SEK | -17.25% |
| 2022 Q2 | 3.41 Million SEK | 4.89% |
| 2021 Q2 | 15.33 Million SEK | -14.94% |
| 2021 Q4 | 3.93 Million SEK | -26.07% |
| 2021 FY | 3.93 Million SEK | -46.84% |
| 2021 Q1 | 18.02 Million SEK | 143.72% |
| 2021 Q3 | 5.31 Million SEK | -65.32% |
| 2020 Q3 | 31.57 Million SEK | 0.0% |
| 2020 Q1 | 36.58 Million SEK | 416.47% |
| 2020 FY | 7.39 Million SEK | 0.0% |
| 2020 Q4 | 7.39 Million SEK | -76.58% |
| 2019 Q4 | 7.08 Million SEK | -87.23% |
| 2019 Q1 | 765.17 Million SEK | 28.71% |
| 2019 Q2 | 88.94 Million SEK | -88.38% |
| 2019 Q3 | 55.47 Million SEK | -37.63% |
| 2018 Q2 | 677.84 Million SEK | 3.55% |
| 2018 FY | 594.51 Million SEK | 0.46% |
| 2018 Q4 | 594.51 Million SEK | -9.82% |
| 2018 Q3 | 659.27 Million SEK | -2.74% |
| 2018 Q1 | 654.63 Million SEK | 10.62% |
| 2017 Q2 | 668.47 Million SEK | 0.62% |
| 2017 Q1 | 664.37 Million SEK | 12.79% |
| 2017 FY | 591.78 Million SEK | 0.47% |
| 2017 Q4 | 591.78 Million SEK | -8.58% |
| 2017 Q3 | 647.29 Million SEK | -3.17% |
| 2016 Q2 | 345.48 Million SEK | 0.4% |
| 2016 Q3 | 438.5 Million SEK | 26.93% |
| 2016 Q4 | 589.04 Million SEK | 34.33% |
| 2016 FY | 589.04 Million SEK | 17572.97% |
| 2016 Q1 | 344.11 Million SEK | 10224.45% |
| 2015 Q4 | 3.33 Million SEK | -94.41% |
| 2015 Q3 | 59.58 Million SEK | -30.62% |
| 2015 FY | 3.33 Million SEK | -80.0% |
| 2015 Q1 | 70.44 Million SEK | 322.71% |
| 2015 Q2 | 85.87 Million SEK | 21.89% |
| 2014 Q4 | 16.66 Million SEK | -72.05% |
| 2014 Q3 | 59.63 Million SEK | -31.34% |
| 2014 Q1 | 74.43 Million SEK | 148.12% |
| 2014 Q2 | 86.85 Million SEK | 16.68% |
| 2014 FY | 16.66 Million SEK | -44.45% |
| 2013 Q1 | 89.64 Million SEK | 124.12% |
| 2013 Q3 | 75.08 Million SEK | -15.08% |
| 2013 FY | 30 Million SEK | -25.0% |
| 2013 Q4 | 30 Million SEK | -60.04% |
| 2013 Q2 | 88.41 Million SEK | -1.37% |
| 2012 Q4 | 40 Million SEK | 102.19% |
| 2012 FY | 40 Million SEK | 0.0% |
| 2012 Q3 | 19.78 Million SEK | 2.44% |
| 2012 Q2 | 19.31 Million SEK | 9.93% |
| 2012 Q1 | 17.56 Million SEK | 0.0% |
| 2011 FY | - SEK | -100.0% |
| 2011 Q2 | 11.34 Million SEK | -6.31% |
| 2011 Q4 | - SEK | -100.0% |
| 2011 Q3 | 11.79 Million SEK | 3.98% |
| 2011 Q1 | 12.1 Million SEK | 7971.4% |
| 2010 FY | 150 Thousand SEK | -50.41% |
| 2010 Q4 | 150 Thousand SEK | 0.0% |
| 2009 FY | 302.5 Thousand SEK | -55.35% |
| 2008 FY | 677.5 Thousand SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 8.8 Million SEK | 46.17% |
| Enzymatica AB (publ) | 26.1 Million SEK | 81.853% |
| Enorama Pharma AB (publ) | 436 Thousand SEK | -986.468% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | 18.93 Million SEK | 74.979% |
| Nanexa AB (publ) | 4.03 Million SEK | -17.485% |
| Newbury Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| ODI Pharma AB | - SEK | -Infinity% |
| Orexo AB (publ) | 473.8 Million SEK | 99.0% |
| Probi AB (publ) | 53.79 Million SEK | 91.195% |
| Swedencare AB (publ) | 1.65 Billion SEK | 99.714% |
| Swedish Orphan Biovitrum AB (publ) | 20.48 Billion SEK | 99.977% |
| Toleranzia AB | 850 Thousand SEK | -457.294% |
| Vivesto AB | 8.16 Million SEK | 42.005% |